The second most common hematologic malignancy worldwide is undergoing profound changes in its treatment. From diagnosis, to initial management, to long term prognosis for the majority of patients, things are looking bright.
Among these seismic changes is a major move by certain physicians, primarily based in the USA, to address the C word. Cure.
Starting in various conferences in 2026, more and more scientists, doctors, and industry representatives started building both a preliminary platform for the definition of cure, as well as hype around the issue. For a chronic malignancy that remains the main cause of death for the majority of patients that live with it, these are bold claims. Are they up to par?
The basics
Multiple myeloma is a B-lymphocyte malignancy involving the last stage of its maturation, namely the plasma cell. These cells normally pump out large numbers of antibodies, both in acute infections, as well as “memory” cells that persist in the bone marrow and lymph nodes and confer long term immunity. That is true for natural infections as well as vaccinations.
While all other malignancies of the B-lymphocyte are typically termed “lymphomas”, multiple myeloma was historically categorized separately, mainly because it arises from the bone marrow (myeloma = cancer from the marrow) rather than the lymph nodes, and because it can cause bone fractures (multiple = many lesions/fractures). You may also see it categorized under the umbrella of “plasma cell dyscrasias”, an old-fashioned way to avoid using words like cancer or malignancy.
Healthy plasma cells may sometimes, for reasons that are not fully elucidated, receive constant chronic signals by the immune system to produce antibodies. In their rush to respond to these demands, some fast-replicating plasma cells may acquire mistakes in parts of their DNA that control the delicate machinery that keeps the antibodies flowing, but under tight surveillance. These mistakes are called mutations and, as with most cancers, they result in a single cell becoming partly or wholly invisible to the immune system and starting to proliferate.
Treatment advancements
In stark contrast to even 10 years ago, when standard 1st line treatment usually resulted in significant but incomplete responses (named Very Good Partial Response, or VGPR), the current state of the art can produce deeper responses in the majority of patients. This is called a Complete Response, or CR.
This brings up the question: if the disease responded completely, why is it not considered cured?
While a significant number of lymphomas can be cured with the current standard of care – usually tailored chemotherapy combined with immunotherapy -, multiple myeloma is a bit more tricky. Its interaction with neighbouring cells in the bone marrow, and certain mutations that may give it an edge result in a bunch of plasma cells wounded but alive after the end of a treatment. Depending on the trick used to stay alive, they either lay dormant and proliferate slowly over many years, or in other cases they expand quickly as soon as the treatment stops. This group of survivor cells is called Measurable Residual Disease, or MRD, and their rebound is called a relapse.
Multiple scientific articles from the US and Europe have in recent years proved that serial negative tests for MRD, meaning multiple tests from the bone marrow or blood that can not detect the plasma cells that survived, is a favourable indicator, meaning the treatment response attained is held for longer, sometimes years, sometimes decades.
Naturally, after more and more patients treated globally with modern regimens achieved sustained MRD negativity, healthcare professionals decided to address the question of cure: Is this group of survivor plasma cells hidden, or is it gone for good?
As with all scientific testing, MRD has its limitations. Different methods offer different sensitivity. High sensitivity means that the test can detect a smaller group of survivors. Sometimes, the test is sensitive enough to detect it even if the myeloma cells represent only 1 in 1 million healthy cells (also called 10-6) . However, a negative result does not guarantee the absence of the survivor cells.
Another problem that arises is that patients treated with modern regimens haven’t been observed for long enough to exclude the possibility of a late relapse. We have only recently exceeded 6 years of median surveillance from trial patients getting the modern treatment protocols. Taking into account that most patients with Multiple Myeloma are expected to survive for more than a decade, it’s difficult to extrapolate data that far.
In essence, while the data are very promising, they are not mature enough.
Conclusion
As of November 2026, multiple groups of scientists all over the world are working tirelessly to reach a preliminary consensus, asking questions like:
- What tools are validated to properly measure MRD?
- What results should be expected from MRD testing at various stages of treatment and surveillance to count towards a cure?
- What is the chance that residual disease escapes detection?
- Are patients with more favourable mutations more likely to be cured? Where is the line drawn?
Until these questions have definitive, authoritative answers backed by very long term data, discussing cure should be framed cautiously.
One thing is clear: we are beating Multiple Myeloma. The final blow is yet to be confirmed.
The above article is aimed at patients and is intended for informative purposes only. It does not constitute medical advice.
No generative AI was used in researching, writing, or editing this article.
Sources:
- Global Myeloma Experts Define Cure for a Disease Long Considered Incurable
- https://ascopubs.org/doi/10.1200/JCO-26-00384?referrer=https%3A%2F%2Fwww.google.com%2F
- https://www.sciencedirect.com/science/article/abs/pii/S0268960X26000524?via%3Dihub
- https://www.youtube.com/watch?v=5eSNhJWmYS8
- https://www.youtube.com/watch?v=OtFRPkLUk3s